334 related articles for article (PubMed ID: 27749327)
21. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
22. Integration of immunotherapy into the management of advanced prostate cancer.
Kantoff P; Higano CS
Urol Oncol; 2012; 30(5 Suppl):S41-7. PubMed ID: 23040162
[TBL] [Abstract][Full Text] [Related]
23. Immunology and immunotherapy approaches for prostate cancer.
Elkord E
Prostate Cancer Prostatic Dis; 2007; 10(3):224-36. PubMed ID: 17420764
[TBL] [Abstract][Full Text] [Related]
24. Current status of immunological approaches for the treatment of prostate cancer.
Drake CG; Antonarakis ES
Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
[TBL] [Abstract][Full Text] [Related]
25. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
McKarney I
Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
[TBL] [Abstract][Full Text] [Related]
26. Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.
Di Lorenzo G; Ferro M; Buonerba C
BJU Int; 2012 Jul; 110(2 Pt 2):E99-104. PubMed ID: 22177289
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.
Lou DY; Fong L
Urol Oncol; 2016 Apr; 34(4):182-92. PubMed ID: 24495446
[TBL] [Abstract][Full Text] [Related]
28. PROSTVAC® targeted immunotherapy candidate for prostate cancer.
Shore ND
Immunotherapy; 2014; 6(3):235-47. PubMed ID: 24762070
[TBL] [Abstract][Full Text] [Related]
29. Therapies in development for castrate-resistant prostate cancer.
Harzstark AL; Ryan CJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T?
Lü C; Williams AK; Chalasani V; Martínez CH; Chin J
Expert Opin Biol Ther; 2011 Jan; 11(1):99-108. PubMed ID: 21080858
[TBL] [Abstract][Full Text] [Related]
31. Current vaccination strategies for prostate cancer.
Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
[TBL] [Abstract][Full Text] [Related]
32. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.
Mulders PF; De Santis M; Powles T; Fizazi K
Cancer Immunol Immunother; 2015 Jun; 64(6):655-63. PubMed ID: 26025563
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy: a glimmer of hope for metastatic prostate cancer.
Jindal V
Chin Clin Oncol; 2018 Dec; 7(6):61. PubMed ID: 29860848
[TBL] [Abstract][Full Text] [Related]
34. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
Buonerba C; Ferro M; Di Lorenzo G
Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
[TBL] [Abstract][Full Text] [Related]
35. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
36. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
37. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
38. Cancer immunotherapy: a paradigm shift for prostate cancer treatment.
Karan D; Holzbeierlein JM; Van Veldhuizen P; Thrasher JB
Nat Rev Urol; 2012 May; 9(7):376-85. PubMed ID: 22641164
[TBL] [Abstract][Full Text] [Related]
39. Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.
Saad F; Miller K
Urology; 2015 May; 85(5):976-986. PubMed ID: 25709051
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
Bilusic M; Heery C; Madan RA
Vaccine; 2011 Sep; 29(38):6485-97. PubMed ID: 21741424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]